A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Background: The US Food and Drug Administration’s accelerated approval and later withdrawal of bevacizumab in patients with metastatic breast cancer (mBC) is a seminal case for ongoing debates about the validity of using progression-free survival (PFS) as a surrogate measure for overall survival (OS) in cancer drug approvals. We systematically reviewed and meta-analyzed the evidence around bevacizumab’s regulatory approval and withdrawal in mBC. Methods: We searched for all published phase II or III clinical trials testing bevacizumab as a first-line therapy for patients with mBC. Data were extracted on trial demographics, interventions, and outcomes. Descriptive analysis was stratified by whether the trial was initiated before, during, or after the accelerated approval. We used a cumulative random-effects meta-analysis to assess the evolution of evidence of the effect of bevacizumab on PFS and OS. We estimated the association between the trial-level PFS and OS effect using a nonlinear mixed-regression model. Results: Fifty-two studies were included. Trial activity dramatically dropped after the accelerated approval was withdrawn. Eight clinical trials reported hazard ratios (hazard ratios) and were meta-analyzed. The cumulative hazard ratio for PFS was 0.72 (95% CI = 0.65 to 0.79), and the cumulative hazard ratio for OS was 0.90 (95% CI = 0.80 to 1.01). The regression model showed a statistically nonsignificant association between PFS benefit and OS benefit (β = 0.43, SE = 0.81). Conclusion: The US Food and Drug Administration’s decision-making in this case was consistent with the evolving state of evidence. However, the fact that seven clinical trials are insufficient to conclude validity (or lack thereof) for a trial-level surrogate suggests that it would be more efficient to conduct trials using the more clinically meaningful endpoints.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The available data show that bevacizumab combined with ChT as first-line therapy for ABC provides a moderate benefit in progression-free survival (PFS) and no benefit in OS.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [35]
In the citing paper
“The ESMO-MCBS v1.1 score for bevacizumab is two.35”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [35]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081 · cited 3×
“based on an improvement in PFS observed in a single multicenter, open-label, randomized study comparing paclitaxel alone to paclitaxel plus bevacizumab (at the time of approval, the bevacizumab arm had not shown an improvement in OS) (5).”
BackgroundMethodCumulative Meta-Analysis of Therapeutic Trials for Myocardial Infarction
Lau, J., Antman, E. M., Jimenez-Silva, J., Kupelnick, B., Mosteller, F., & Chalmers, T. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207233270406 · Cited by 1,140 · cited 1×
“We analyzed the evidence on the effect of bevacizumab on PFS and OS over time using a cumulative random-effects metaanalysis (9).”
MethodRobert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064 · cited 2×
“All seven trials that reported an hazard ratio for OS found no survival benefit with addition of bevacizumab, but each was small and not well powered to identify moderate effect sizes (5,13,15,24,29,36).”
BackgroundMethodMiles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897 · cited 2×
“All seven trials that reported an hazard ratio for OS found no survival benefit with addition of bevacizumab, but each was small and not well powered to identify moderate effect sizes (5,13,15,24,29,36).”
BackgroundMethodKim, C., & Prasad, V. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.5868 · Cited by 354 · cited 2×
“clinical trials of metastatic breast cancer (mBC) treatments, and many investigational drugs have earned approval from the US Food and Drug Administration (FDA) for mBC on the basis of a statistically significant improvement in PFS (1).”
BackgroundResultAssessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
Gyawali, B., Hey, S. P., & Kesselheim, A. S. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0462 · Cited by 300 · cited 1×
“A recent analysis of the FDA–mandated confirmatory trials for new cancer therapies that received accelerated approval based on a surrogate endpoint also found that many confirmatory trials used the same surrogate endpoint for their primary outcome, and that in some cases, a negative outcome in the confirmatory trial d…”
BackgroundSelf-citationGianni, L., Romieu, G. H., Lichinitser, M., Serrano, S. V., Mansutti, M., Pivot, X., Mariani, P., Andre, F., Chan, A., Lipatov, O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7912 · Cited by 254 · cited 2×
“All seven trials that reported an hazard ratio for OS found no survival benefit with addition of bevacizumab, but each was small and not well powered to identify moderate effect sizes (5,13,15,24,29,36).”
BackgroundResultRugo, H. S., Barry, W. T., Moreno-Aspitia, A., Lyss, A. P., Cirrincione, C., Leung, E., Mayer, E. L., Naughton, M., Toppmeyer, D., Carey, L. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5298 · Cited by 222 · cited 1×
“8%) involved administering bevacizumab in all study arms (23,30,35).”
BackgroundOutcomes and endpoints in trials of cancer treatment: the past, present, and future
Wilson, M. K., Karakasis, K., & Oza, A. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70375-4 · Cited by 219 · cited 1×
“Meta-analyses of the association between PFS and OS in mBC trials have not always produced consistent results (2), and consequently, the use of PFS as a surrogate endpoint in this setting remains controversial (3).”
Result
Research works printed but not linked: 1
- Pazdur, 2010, Regulatory Decision to Withdraw Avastin (Bevacizumab) First-Line Metastatic Breast Cancer Indication
Cited by
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“1 score for bevacizumab is two.(35) Some experts believe it can be a good option for situations of extensive cutaneous inflammatory disease due to its potential antiangiogenic effect.”
Invasion and metastasis in cancer: molecular insights and therapeutic targets
Li, Y., Liu, F., Cai, Q., Deng, L., Ouyang, Q., Zhang, X. H.-F., & Zheng, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02148-4 · Cited by 244
Liu, J., Liu, Q., Li, Y., Li, Q., Su, F., Yao, H., Su, S., Wang, Q., Jin, L., Wang, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000696 · Cited by 183
“AST, aspartate aminotransferase.”
Gyawali, B., Hey, S. P., & Kesselheim, A. S. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100332 · Cited by 162
Self-citationBreast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies
Wang, Y., Ye, F., Liang, Y., & Yang, Q. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01424-8 · Cited by 150
Metadata
- Authors
- Hey, S. P., Gyawali, B., D’Andrea, E., Kanagaraj, M., Franklin, J. M., & Kesselheim, A. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Corresponding author
- Hey, Spencer Phillips
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-25
- Volume
- 112
- Issue
- 4
- Pages
- 335-342
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC7156929
- OpenAlex
- W2982249510
- Cited by
- 29
- References
- 42
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 3
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Arnold Ventures
- Harvard-MIT Center for Regulatory Science
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- bevacizumab, metastatic breast cancer, first-line therapy, accelerated approval, surrogate endpoints, progression-free survival, overall survival, FDA regulatory decision-making
- MeSH terms
- Bevacizumab, Antineoplastic Agents, Immunological, Progression-Free Survival, Breast Neoplasms, Decision Making, Female, Humans, Legislation, Drug, Neoplasm Metastasis, Regression Analysis, United States, United States Food and Drug Administration, Survival Rate, Randomized Controlled Trials as Topic, Drug Approval, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Nonlinear Dynamics, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises. https://app.cochat.ai/papers/10.1093/jnci/djz211
- The paper
- Hey, S. P., Gyawali, B., D’Andrea, E., Kanagaraj, M., Franklin, J. M., & Kesselheim, A. S. (2020). A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djz211
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.